WEIGHT LOSS PHARMACOTHERAPY: BRIEF SUMMARY OF THE CLINICAL LITERATURE AND COMMENTS ON RACIAL DIFFERENCES
WEIGHT LOSS PHARMACOTHERAPY: BRIEF SUMMARY OF THE CLINICAL LITERATURE AND COMMENTS ON RACIAL DIFFERENCES
复制标题
DOI：
10.18865/ed.25.4.511
复制
发表时间：
2015-09-01
影响因子：
3.2
通讯作者：
White, Kellee
中科院分区：
文献类型：
--
作者：
Egan, Brent M.;White, Kellee
白人、黑人和西班牙人，尤其是女性，肥胖率的差异是惊人的。此外，在任何给定的体重指数或腹围下，黑人、西班牙裔和其他少数种族的糖尿病发病率都高于白人。除了不断增加的健康负担外，到2030年，肥胖的总成本可能超过5000亿美元。经批准长期使用的抗肥胖药物治疗与改变生活方式相结合，可使体重较基线减轻5%-15%。体重减轻5%与医疗效益相关，包括减少糖尿病和心血管风险。虽然在美国人群中，经过一年或更长时间的医学减肥比以前在许多临床试验中看到的要好，但大约60%的成年人无法维持5%的体重减轻。被批准用于长期减肥的药物疗法可能会让更多的受试者保持健康的体重减轻。
The disparity in obesity rates between White, Black, and Hispanic individuals, especially women, is striking. Moreover, at any given body mass index or abdominal girth, incident diabetes is greater in Black, Hispanic and other racial-ethnic minorities than Whites. In addition to the growing health burden, the total costs of obesity in 2030 could exceed $500 billion (USD). Weight loss of 5%-15% from baseline can be attained with anti-obesity pharmacotherapy approved for long-term use in combination with lifestyle change. Weight loss of >= 5% is associated with medical benefits including reduction of incident diabetes and cardiovascular risk. While medical weight loss after one year or more in the US population is better than previously seen in many clinical trials, >60% of adults fail to sustain a 5% weight loss. Drug therapies approved for long-term weight loss may permit even more subjects to sustain healthful weight reduction.